Zhang Jialin, Xu Xinyu, Zhou Yeyue, Su Jingyang, Wang Jue
Department of Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, China.
Department of General internal medicine, Tongde Hospital Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzhou, China.
Front Oncol. 2025 Mar 4;15:1472407. doi: 10.3389/fonc.2025.1472407. eCollection 2025.
The objective of this study was to assess the effectiveness and safety of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer by using meta-analysis.
To gather comprehensive and reliable data for our analysis, we systematically searched multiple databases for relevant studies. We utilized RevMan5.3 software to perform the meta-analysis.
Following a rigorous screening and evaluation process, we ultimately included a total of 13 studies in our analysis. Our findings showed that compared to endocrine therapy alone, the combination of CDK4/6 inhibitors with endocrine therapy significantly increased both PFS [HR 0.54 (95%CI: 0.50, 0.58), ], OS [HR 0.77 (95%CI: 0.50, 0.58), ] and ORR [RR 1.39 (95% CI: 1.21, 1.60), ). However, it was also found that CDK4/6 inhibitors caused adverse drug reactions related to the blood system and digestive system ().
Our meta-analysis demonstrates that the addition of CDK4/6 inhibitors to endocrine therapy can result in improved PFS and OS for HR+ breast cancer patients. Meanwhile, we recommend close monitoring and management of these potential side effects when utilizing these inhibitors in breast cancer treatment.
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023490499.
本研究的目的是通过荟萃分析评估细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂治疗激素受体阳性（HR+）乳腺癌的有效性和安全性。
为收集全面且可靠的数据进行分析，我们系统检索了多个数据库以查找相关研究。我们使用RevMan5.3软件进行荟萃分析。
经过严格的筛选和评估过程，我们最终在分析中纳入了总共13项研究。我们的研究结果表明，与单纯内分泌治疗相比，CDK4/6抑制剂与内分泌治疗联合使用显著提高了无进展生存期[风险比（HR）0.54（95%置信区间：0.50，0.58）]、总生存期[HR 0.77（95%置信区间：0.50，0.58）]和客观缓解率[相对危险度（RR）1.39（95%置信区间：1.21，1.60）]。然而，还发现CDK4/6抑制剂会引起与血液系统和消化系统相关的药物不良反应（）。
我们的荟萃分析表明，在内分泌治疗中添加CDK4/6抑制剂可改善HR+乳腺癌患者的无进展生存期和总生存期。同时，我们建议在乳腺癌治疗中使用这些抑制剂时密切监测和管理这些潜在的副作用。
